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MEMORANDUM FROM THE ARTS AND HUMANITIES RESEARCH 
COUNCIL TO THE HOUSE OF LORDS SCIENCE AND TECHNOLOGY 
COMMITTEE INQUIRY INTO GENOMIC MEDICINE 
 
1. The Arts and Humanities Research Council (AHRC) welcomes this opportunity to 
respond to the committee’s inquiry. This response does not include or necessarily 
reflect the views of the Science and Innovation Group in the Department for 
Innovation, Universities and Skills.  
 
2. The AHRC supports research within a huge subject domain from traditional 
humanities subjects, such as history, modern languages and English literature, to 
the creative and performing arts. The AHRC funds research and postgraduate 
study within the UK's higher education institutions. In addition, on behalf of the 
Higher Education Funding Council for England, it provides funding for museums, 
galleries and collections that are based in, or attached to, higher education 
institutions in England. 
 
3. This information in this response comes (except the Research and Scientific 
Development section, as indicated below) from Professor Graeme Laurie, Director 
of the AHRC Research Centre for Studies in Intellectual Property and Technology 
Law at the University of Edinburgh and Mr Shawn Harmon, Research Associate 
with the AHRC Centre and with Innogen (sponsored by the ESRC) also at the 
University of Edinburgh. The response focuses on issues from the legal, ethical 
and/or regulatory perspectives, being the focus of the work of the AHRC Law 
Centre. Further details can be seen at http://www.law.ed.ac.uk/ahrc and also 
http://www.innogen.ac.uk. 
 
Policy Framework 
 
• Does the existing regulatory and advisory framework provide for optimal 
development and translation of new technologies? Are there any regulatory 
gaps? 
 
4. We contend that the existing regulatory framework does not optimise the 
development and translation of new technologies. There are three hurdles of 
particular significance.  
 
5. Regulatory Joined-up-ness: There exists ‘innovation drag’ as a result of regulatory 
complexities (e.g.: regulatory overlap and co-regulation by a variety of bodies, 
from the Human Fertilisation and Embryology Authority (HFEA) and Human 
Tissue Authority (HTA), to UK Stem Cell Bank (UKSCB), to the General 
Medical Council, the patents regime and more. The inefficiencies created by 
multiple overlapping recommendations, directions, guidances, and laws from 
bodies/agencies (who do not necessarily coordinate or even communicate) with an 
interest in different but overlapping stages of innovation, complicates and 
elongates the journey from idea to socially-useful output. It also makes it difficult 
for public actors to steer innovation in socially-useful directions. In short, there 
needs to be regulatory ‘joined-upness’ so as to promote timely and valuable 
innovation. The Committee has the opportunity to map these regulatory pathways 
 
 
 
and to recommend how more effective and efficient trajectories might be 
developed. 
 
6. The role of ethics committees: A particular ‘pressure point’ in this arena – that is, 
activities directed at the translation of research into products/processes directed at 
humans –  which deserves closer attention is the remit and transparency of local or 
multi-centre ethics committees; more particularly, how to articulate the scope of 
the former and ensure the latter. 
 
7. Access to research data: There are barriers to researcher/innovator access to data 
and much work has been done with a view to examining the knowledge enclosure 
tendencies of existing intellectual property regimes. The Committee is, however, 
in a position to examine the UK intellectual property regime and its interactions 
with European and international institutions, and more particularly the application 
of these regimes to genomic medicine. One fruitful avenue to monitor in depth is 
the initiative from the UK Stem Cell Bank to rely more on Open Science. It is far 
from clear that this will serve the range of stakeholder interests.   
 
• In what way is science and clinical policy decision-making informed by social, 
ethical and legal considerations? 
 
8. We would suggest that there are five core challenges facing the optimal 
governance of genomic medicine and which involve the above considerations. 
 
9. Consent: The imperative to obtain informed consent has become the dominant 
paradigm in biomedical governance but we would point out that its origins lie in 
medical research focussed on the human body and that its application to research 
involving medical or genomic data should be explored in more depth. Such an 
imperative may stand in the way of valuable medical research and act as a hurdle 
to striking an optimal balance of interests. Consent is not a social value in itself, 
but merely a means to respect individuals and their interests; as we indicate below, 
it is neither necessary nor sufficient to protect the core individual interests 
involved in research involving medical/genomic data, viz privacy interests. We 
would urge the Committee to explore the debate about the value and limits of 
consent and to ask whether we ‘fetishise’ consent as a regulatory tool at the 
expense of other options.  
 
10. Confidentiality: As a recent report from the Academy of Medical Sciences 
indicates1, the current regulatory regime that operates within the United Kingdom 
with respect to protection of privacy does not take advantage of flexibilities within 
the law which provide for the adequate protection of privacy while also promoting 
medical research when informed consent is neither practicable nor possible. We 
would also refer the Committee to the recent report from the Article 29 Working 
Party on Data Protection which discusses e-health records and the possibility of 
regulation regimes that promote a public interest mandate.2 We would urge the 
                                                 
1 Academy of Medical Sciences on Personal Data for Public Good: Using Health Information in Medical Research 
(2006), report available here: 
http://www.acmedsci.ac.uk/p99puid62.html 
2 Article 29 Data Protection Working Party, ‘Working Document on the processing of personal data 
relating to health in electronic health records (EHR)’ 15 February 2007. 
 
 
 
Committee to consider, in particular, the role and approach of the Patient 
Information Advisory Group which takes a very consent-based stance to its work. 
This can be contrasted with the Privacy Advisory Committee for Scotland, of 
which Professor Graeme Laurie is Chair, and which seeks a balance of public and 
private interests.3 
 
11. Confidence: Public trust and confidence is crucial to effective governance regimes 
and we would suggest that particular close attention should be paid to questions of 
access to genomic data. Good governance regimes should be transparent, robust, 
reasonable, involve clear due process for all parties, and be subject to effective 
oversight. We would point to the example of the UK Biobank Ethics and 
Governance Council, chaired by Professor Graeme Laurie, which is developing 
considerable experience in this realm; crucial to the success of the Council is a 
close working relationship with UK Biobank itself. 
 
12. Commercialisation: Our research, and that of others, has revealed some evidence 
of public unease about the role of commercialisation of genetic/genomic 
research.4 While we accept commercialisation as a reality, we would nonetheless 
suggest that the Committee consider carefully whether and how such public 
attitudes might be taken into account. 
 
13. Collaboration: International collaboration is essential if we are to realise the full 
promise of genomic medicine. The same is true in terms of governance, and in 
many ways the United Kingdom is leading the international field; once again, we 
offer the example of the UK Biobank Ethics and Governance Council. On 
international collaboration, we would also point to the example of the Public 
Population Project in Genomics (P3G) which is seeking harmonisation of efforts, 
both scientific and regulatory, among biobanks across the globe.5 
 
Research and Scientific Development 
 
• What is the state of the science? What new developments are there? What is the 
rate of change? 
 
14. The AHRC has funded ‘Philosophical Issues in Genomics’; a research grant 
award made to Professor John Dupré and Dr Maureen O’Malley at the ESRC 
Centre for Genomics in Society (Egenis); the information in this section comes 
from them. The award of £93,838 ran from 01/03/06 to 29/02/08 and addressed 
two topics that have enormous potential for relevance to future medical practice; 
systems biology and microbiology. Systems biology is an attempt to apply 
sophisticated computational methods to modelling complex biological systems. It 
is widely seen as a successor science to genomics, and is in part a response to the 
growing realisation that the once widespread assumption that causation ran in a 
linear fashion from DNA through RNA to proteins is entirely mistaken. Systems 
                                                 
3 Privacy Advisory Committee for Scotland, more information here: 
http://www.isdscotland.org/isd/2466.html 
4 Haddow, G., Laurie, G., Cunningham-Burley, S., & K. Hunter, ‘Tackling Community Concerns About 
Commercialisation and Genetic Research: A Modest Interdisciplinary Proposal’ (2007) Social Science and 
Medicine, 64: 272-282. 
5 Population Project in Genomics: http://www.p3gconsortium.org/ 
 
 
 
biology explores the networks of typically cyclical and feedbacked causal 
interactions that constitute the functioning of biological systems. Although 
research in this area has yet to reach the point where it is directly applicable to 
interventions in human biological systems, this is likely to change. One area that is 
widely anticipated is the use, in part, of in silico models deriving from systems 
biology for the testing and discovery of new drugs. 
 
15. Metagenomics can be seen as a subarea of systems biology. The systems it 
explores are microbial communities, reflecting the understanding that microbes 
generally function not as isolated individuals but rather as complex communities 
of cooperating microbes with very complex division of labour. This field has 
almost unlimited potential impact on medicine. About 90% of the cells that 
constitute the functioning human body are in fact microbial symbionts, and about 
99% of the genes in a human body reside in these microbes. The human 
microbiome project is now beginning the project of cataloguing these genes. 
Microbial symbionts are now understood to be essential for human functioning, in 
areas including most notably digestion, immune response, and development. There 
is growing evidence that gene expression is mutually modulated by human and 
symbiotic microbial cells. These developments present nothing less than a 
reconceptualisation of what a human body is, and can therefore potentially 
revolutionise our understanding of the system that medicine aims to influence. 
 
16. Work in Egenis to date has been concerned primarily with mapping these 
developments and communicating to scholars in a range of disciplines (including 
philosophers of biology) the importance of the insufficient attention that has been 
paid to microbes. Further research is planned by the award holders to expand this 
work in the direction of its relevance to medical practice. 
 
 
Data Use and Interpretation  
 
• What are the implications of the generation and storage of genome data on 
personal data security and privacy, and on its potential use or abuse in 
employment and insurance? How should these be addressed? 
 
17. The Committee should have reference to the quality work that has already been 
undertaken in the area of data storage, data security and data use in the genomic 
context.6  Generally, the issues of concern in the employment and insurance 
context – which turn on genetic determinism, consent, discrimination, and data 
security – have not changed. 
 
Translation 
 
• How meaningful are genetic tests which use genome variation data? What 
progress has been made in the regulation of such tests?  
 
                                                 
6  See Nuffield Council, Genetic Screening: Ethical Issues (London: NCB, 1993), chs. 6 and 7 Human 
Genetics Commission, Whose Hands On Your Genes? A Discussion Document on the Storage, Protection and Use of 
Personal Genetic Information (London: HGC, 2001), Human Genetics Commission, Inside Information: Balancing 
Interests in the Use of Personal Genetic Data (London: HGC, 2002),. 
 
 
 
18. Again, there has been extensive consideration of the ethical, legal, social and 
practical aspects of this issue.7 
 
19. In addition to Genes Direct (2003),8 the Human Genetics Commission (HGC) has 
recently issued a new report entitled More Genes Direct (2007),9 which identifies 
key issues in the genetic testing area as (1) pre-market review of tests, (2) quality 
assurance of testing services, (3) advertising and promotion controls, and (4) 
access to independent, impartial advice on the part of consumers. The HGC rightly 
identify a need for stricter controls in this field combined with improved NHS 
genetics services, and recommends that certain tests should only be offered 
through qualified health professionals. We endorse this position. 
 
20. There are also on-going concerns about international access to, and internet 
marketing of, genetic tests. In 2007, the OECD adopted Guidelines aimed at 
quality assurance, analytic accuracy of tests, and information provision,10 and 
EuroGentest is examining the possibility of requiring labs, clinical services and 
professionals to be (ISO) accredited.11  Generally, it is recognised that there needs 
to be accelerated cooperation around international standardisation of definitions, 
harmonisation of quality assurance standards, and controls on advertising and 
administering tests. Use of the internet makes harmonisation and regulatory 
cooperation all the more critical. 
 
21. The above supports the claim that there is still much to do in the regulation of this 
field and in managing/rationalising the provision of genetic testing services. 
 
 
 
Use of genomic information in a healthcare setting 
 
• How useful will genomic information be as part of individualised medical 
advice? What provisions are there for ensuring that the individual will be able to 
understand and manage genomic information, uncertainty and risk? 
 
• Should there be a regulatory code (mandatory or voluntary) covering the 
provision of this advice? 
 
22. There is already a plethora of advice and guidance in existence about the handling 
of medical/genetic data. We would caution against yet another iteration unless this 
comes from a sufficiently high-level, authoritative body and is accompanied by a 
clear explanation of how this new guidance should be read with existing 
provisions.  
                                                 
7  See ECG, Ethical, Legal and Social Aspects of Genetic Testing: Research, Development and Clinical 
Applications (Brussels: EU, 2004), and the ongoing work of EuroGentest (http://www.eurogentest.org/), 
an EU-funded Network of Excellence with a remit of encouraging harmonisation of standards and 
practices throughout the EU and beyond. 
8  HGC, Genes Direct: Ensuring the Effective Oversight of Genetic Tests Supplied Directly to the Public 
(London: HGC, 2003). 
9  HGC, More Genes Direct: A Report on Developments in the Availability, Marketing and Regulation of Genetic 
Tests Supplied Directly to the Public (London: HGC, 2007). 
10  OECD, Guidelines for Quality Assurance in Molecular Genetic Testing (Paris: OECD, 2007). 
11  See EuroGentest, Recommendations for Genetic Counselling Related to genetic Testing (Draft 2), 2007. 
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